MX2019000277A - Conjugados polimero-farmaco escindibles. - Google Patents
Conjugados polimero-farmaco escindibles.Info
- Publication number
- MX2019000277A MX2019000277A MX2019000277A MX2019000277A MX2019000277A MX 2019000277 A MX2019000277 A MX 2019000277A MX 2019000277 A MX2019000277 A MX 2019000277A MX 2019000277 A MX2019000277 A MX 2019000277A MX 2019000277 A MX2019000277 A MX 2019000277A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugates
- polymer drug
- cleavable polymer
- polymer
- side chains
- Prior art date
Links
- 239000000580 polymer-drug conjugate Substances 0.000 title abstract 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
- C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
- C08F220/603—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen and containing oxygen in addition to the carbonamido oxygen and nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/10—Esters
- C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
- C08F222/106—Esters of polycondensation macromers
- C08F222/1063—Esters of polycondensation macromers of alcohol terminated polyethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con conjugados polímero-fármaco que comprenden una estructura principal de polímero formada a base de (met)acrilato con por lo menos dos tipos de cadenas laterales, en donde una de las cadenas laterales es una cadena de polietilenglicol (PEG) y la otra cadena lateral comprende por lo menos un agente terapéutico unido de manera covalente a un enlazador escindible, con métodos para preparar dichos conjugados polímero-fármaco y con su uso para el tratamiento de enfermedades tales como cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1611405.0A GB2551979A (en) | 2016-06-30 | 2016-06-30 | Cleavable polymer drug conjugates |
PCT/IB2017/053567 WO2018002761A1 (en) | 2016-06-30 | 2017-06-15 | Cleavable polymer drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000277A true MX2019000277A (es) | 2019-05-27 |
Family
ID=56891421
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000277A MX2019000277A (es) | 2016-06-30 | 2017-06-15 | Conjugados polimero-farmaco escindibles. |
MX2024000877A MX2024000877A (es) | 2016-06-30 | 2019-01-07 | Conjugados polimero-farmaco escindibles. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2024000877A MX2024000877A (es) | 2016-06-30 | 2019-01-07 | Conjugados polimero-farmaco escindibles. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20190321479A1 (es) |
EP (2) | EP3478323B1 (es) |
JP (1) | JP6937329B2 (es) |
KR (2) | KR20230035709A (es) |
CN (1) | CN109475637A (es) |
AU (1) | AU2017286869B2 (es) |
BR (1) | BR112019000029A2 (es) |
CA (1) | CA3029318A1 (es) |
DK (1) | DK3478323T3 (es) |
EA (1) | EA038984B1 (es) |
ES (1) | ES2966774T3 (es) |
FI (1) | FI3478323T3 (es) |
GB (1) | GB2551979A (es) |
HR (1) | HRP20231642T1 (es) |
HU (1) | HUE064705T2 (es) |
IL (2) | IL263965B2 (es) |
MX (2) | MX2019000277A (es) |
PL (1) | PL3478323T3 (es) |
PT (1) | PT3478323T (es) |
WO (1) | WO2018002761A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
GB2556055B (en) | 2016-11-16 | 2022-03-23 | Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti | Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments |
CN111615405B (zh) * | 2017-11-17 | 2023-11-28 | 国家科学研究中心 | 聚合物前药及其皮下和/或肌内给药 |
CN108752507A (zh) * | 2018-05-12 | 2018-11-06 | 辽宁大学 | 一种酶敏感和氧化还原敏感双重响应型共聚物及其制备方法和应用 |
KR20220072851A (ko) * | 2019-09-26 | 2022-06-02 | 스타파마 피티와이 리미티드 | 치료용 덴드리머 |
CN112608364B (zh) * | 2020-12-09 | 2023-08-29 | 四川瀛瑞医药科技有限公司 | 一种果胶-阿霉素轭合物及其中间体的制备方法 |
CN115010913B (zh) * | 2022-06-17 | 2023-05-26 | 广东工业大学 | 一种pH/还原双重响应聚合物胶束及其制备方法与应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US6338843B1 (en) | 1997-06-12 | 2002-01-15 | Ml Laboratories | Biologically active materials |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
CZ297827B6 (cs) | 2005-09-05 | 2007-04-04 | Zentiva, A. S. | Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva |
US8017141B2 (en) * | 2006-12-15 | 2011-09-13 | Advanced Cardiovascular Systems, Inc. | Coatings of acrylamide-based copolymers |
US9434610B2 (en) * | 2008-10-07 | 2016-09-06 | Rexahn Pharmaceuticals, Inc. | HPMA—docetaxel conjugates and uses therefore |
CZ303072B6 (cs) * | 2009-02-13 | 2012-03-21 | Zentiva, K.S. | Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika |
KR101721865B1 (ko) * | 2009-10-13 | 2017-04-03 | 렉산 파마슈티컬스, 인코포레이티드 | 항암제의 전달을 위한 폴리머 시스템 |
JP5681285B2 (ja) * | 2010-07-28 | 2015-03-04 | コーニング インコーポレイテッド | 細胞培養コーティングのためのプレポリマー調製品 |
WO2014152451A2 (en) * | 2013-03-14 | 2014-09-25 | University Of Rochester | Compositions and methods for controlled localized delivery of bone forming therapeutic agents |
CN105168230B (zh) * | 2015-09-02 | 2019-01-22 | 上海市普陀区中心医院 | 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法 |
-
2016
- 2016-06-30 GB GB1611405.0A patent/GB2551979A/en not_active Withdrawn
-
2017
- 2017-06-15 KR KR1020237007512A patent/KR20230035709A/ko not_active Application Discontinuation
- 2017-06-15 HR HRP20231642TT patent/HRP20231642T1/hr unknown
- 2017-06-15 AU AU2017286869A patent/AU2017286869B2/en active Active
- 2017-06-15 MX MX2019000277A patent/MX2019000277A/es unknown
- 2017-06-15 EP EP17733906.6A patent/EP3478323B1/en active Active
- 2017-06-15 JP JP2018569157A patent/JP6937329B2/ja active Active
- 2017-06-15 PT PT177339066T patent/PT3478323T/pt unknown
- 2017-06-15 WO PCT/IB2017/053567 patent/WO2018002761A1/en active Search and Examination
- 2017-06-15 IL IL263965A patent/IL263965B2/en unknown
- 2017-06-15 HU HUE17733906A patent/HUE064705T2/hu unknown
- 2017-06-15 BR BR112019000029-1A patent/BR112019000029A2/pt active Search and Examination
- 2017-06-15 EP EP23178285.5A patent/EP4260874A1/en active Pending
- 2017-06-15 CN CN201780045704.2A patent/CN109475637A/zh active Pending
- 2017-06-15 KR KR1020197002227A patent/KR102539137B1/ko active IP Right Grant
- 2017-06-15 CA CA3029318A patent/CA3029318A1/en active Pending
- 2017-06-15 IL IL302564A patent/IL302564A/en unknown
- 2017-06-15 ES ES17733906T patent/ES2966774T3/es active Active
- 2017-06-15 DK DK17733906.6T patent/DK3478323T3/da active
- 2017-06-15 PL PL17733906.6T patent/PL3478323T3/pl unknown
- 2017-06-15 EA EA201990142A patent/EA038984B1/ru unknown
- 2017-06-15 US US16/314,328 patent/US20190321479A1/en active Pending
- 2017-06-15 FI FIEP17733906.6T patent/FI3478323T3/fi active
-
2019
- 2019-01-07 MX MX2024000877A patent/MX2024000877A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20190321479A1 (en) | 2019-10-24 |
AU2017286869B2 (en) | 2022-05-05 |
MX2024000877A (es) | 2024-02-09 |
CA3029318A1 (en) | 2018-01-04 |
JP2019527209A (ja) | 2019-09-26 |
PL3478323T3 (pl) | 2024-03-04 |
BR112019000029A2 (pt) | 2019-04-24 |
FI3478323T3 (fi) | 2023-12-20 |
PT3478323T (pt) | 2024-01-02 |
EP3478323A1 (en) | 2019-05-08 |
IL263965A (en) | 2019-01-31 |
IL302564A (en) | 2023-07-01 |
AU2017286869A8 (en) | 2019-02-14 |
HUE064705T2 (hu) | 2024-04-28 |
CN109475637A (zh) | 2019-03-15 |
DK3478323T3 (da) | 2024-01-02 |
WO2018002761A1 (en) | 2018-01-04 |
EA038984B1 (ru) | 2021-11-18 |
KR102539137B1 (ko) | 2023-06-01 |
KR20190022718A (ko) | 2019-03-06 |
EA201990142A1 (ru) | 2019-06-28 |
KR20230035709A (ko) | 2023-03-14 |
IL263965B2 (en) | 2023-10-01 |
EP4260874A1 (en) | 2023-10-18 |
HRP20231642T1 (hr) | 2024-03-15 |
GB2551979A (en) | 2018-01-10 |
EP3478323B1 (en) | 2023-09-27 |
AU2017286869A1 (en) | 2019-02-07 |
JP6937329B2 (ja) | 2021-09-22 |
ES2966774T3 (es) | 2024-04-24 |
IL263965B1 (en) | 2023-06-01 |
GB201611405D0 (en) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024000877A (es) | Conjugados polimero-farmaco escindibles. | |
EA202290091A1 (ru) | Конъюгат цитотоксического агента с клеточно-связывающей молекулой с разветвленными линкерами | |
PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
NZ754811A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
CL2020001600A1 (es) | Un conjugado de un análogo de tubulisina con enlazadores ramificados. | |
MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
CY1112278T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους | |
NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
WO2017112825A3 (en) | Polymer conjugates having reduced antigenicity and methods of using the same | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
MX2018008061A (es) | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. | |
NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
MX2023013592A (es) | Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas. | |
MX2013003452A (es) | Conjugados de amatoxina con enlazantes mejorados. | |
NZ706853A (en) | Vegf neutralizing prodrugs for the treatment of ocular conditions | |
EP2949344A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
MX2021003184A (es) | Hidrogeles de acido hialuronico degradables. | |
MX2011003738A (es) | Conjugados hpma-docetaxel o gemcitabine y sus usos asociados. |